Skip to content

Cognitive-Behavioral Therapy for Pain and Opioid Dependence in Methadone Maintenance Treatment

Comparison of Cognitive-Behavioral Therapy and Methadone Drug Counseling for Methadone-Maintained Patients With Co-occurring Chronic Pain and Opioid Dependence

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01334580
Enrollment
40
Registered
2011-04-13
Start date
2011-04-30
Completion date
2014-09-30
Last updated
2020-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain, Opiate Dependence

Brief summary

This study involves the comparison of two treatment approaches for patients with chronic pain who are entering methadone maintenance treatment (MMT) for opioid addiction: (a) an integrated counseling that addresses both chronic pain and opioid dependence(POD)and (b) a counseling intervention that addresses opioid dependence only.

Interventions

BEHAVIORALCognitive-Behavioral Therapy for Pain and Opioid Dependence

CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.

BEHAVIORALMethadone Drug Counseling

Methadone Drug Counseling (MDC)is provided by skilled drug counselors over a 12-week period. The primary goal of MDC is cessation of illicit drugs.

Sponsors

National Institute on Drug Abuse (NIDA)
CollaboratorNIH
Yale University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years of age or older * prescription opioid or heroin addiction * moderate to severe chronic pain * enrolled in methadone maintenance at the APT Foundation for opioid addiction * understand English

Exclusion criteria

* current suicide or homicide risk * life-threatening or unstable medical problem

Design outcomes

Primary

MeasureTime frame
Pain reduction16 weeks
Reduce illicit opioid use16 weeks

Secondary

MeasureTime frame
Finalization of treatment manuals16 weeks
Development and modification of therapy training and process rating measures16 weeks

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026